Vanzacaftor/tezacaftor/deutivacaftor

< Vanzacaftor < tezacaftor

Vanzacaftor/tezacaftor/deutivacaftor
Combination of
VanzacaftorMedication
TezacaftorMedication
DeutivacaftorCFTR potentiator
Clinical data
Trade namesAlyftrek
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Vanzacaftor/tezacaftor/deutivacaftor, sold under the brand name Alyftrek, is a fixed-dose combination medication used for the treatment of cystic fibrosis. It is a combination of deutivacaftor, a CFTR potentiator; tezacaftor; and vanzacaftor, as the calcium salt, vanzacaftor calcium dihydrate. It is taken by mouth.

The combination was approved for medical use in the United States in December 2024.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.